Replies to post #162972 on Avid Bioservices Inc (CDMO)

[biopharm]

thats part of the reason that Elliot Sigal probably left as well

... Elliot Sigal, still find it interesting that he and Dr. David Parkinson both find their ways to NEA = New Enterprise Associates and looks like Elliot Sigal leaves BMS only to find himself looking for other ways to provide that optimal immune response: with AdaptImmune

Adaptimmune uses T cell therapy to treat cancer.
...
..
Adaptimmune is a bientech company based in UK and USA. Board of Directors is composed by Jonathan Knowles, James Noble, David Mott-NEA, Elliott Sigal-NEA, Ian Laing, Ali Behbahani-NEA and Peter Thompson(OrbiMed).

http://biotech-365.com/adaptimmune-engineered-increased-affinity-t-cell-receptors/

now why would Adaptimmune take on NEA associates Elliot Sigal, Ali Behbahani and David Mott ? oh... because they accept their seed money! and I could dig deeper but its getting late here and we clearly see 4 BOD's above are tied to seed money and these guys make money whether Adaptimmune is successful or NOT. That is 4 storefront bought BOD's vs 3 others which may also be tied to other seed money but yes... sleep time.

What a vicious game cycle it is.... no wonder why so many lobbied to have a change of control of Peregrine Pharmaceuticals BOD's, because if you control the BOD, you control the outcome and the buyout which would have happened years ago (for pennies on the dollars) of the astronomical value to come and foreseen by the current Peregrine Pharmaceuticals Board of Directors.

------------------

(Oxford, UK and Philadelphia, PA, 25 September 2014). Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round.

The oversubscribed round was led by New Enterprise Associates (NEA), and additional new investors participating included OrbiMed Advisors LLC, Wellington Management Company, LLP, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo A/S, QVT, Rock Springs Capital, venBio Select and Merlin Nexus. Existing investors participating included the University of Oxford and others.

http://www.nea.com/news/press-releases/adaptimmune-secures-104-million-in-series-a-financing

--------------------

Thankfully... Peregrine does not need to depend on NEA and the next additions to Peregrines BOD's just may reveal who will be funding much of them.